東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Genomic effects of interferon-beta i...

Santos, Roseane Maia.

FindBook

Google Book

Amazon

博客來

Genomic effects of interferon-beta in multiple sclerosis patients.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Genomic effects of interferon-beta in multiple sclerosis patients./
作者:	Santos, Roseane Maia.
面頁冊數:	260 p.
附註:	Source: Dissertation Abstracts International, Volume: 65-12, Section: B, page: 6314.
Contained By:	Dissertation Abstracts International65-12B.
標題:	Health Sciences, Pharmacy. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3156977
ISBN:	0496895486

Genomic effects of interferon-beta in multiple sclerosis patients.
Santos, Roseane Maia.

Genomic effects of interferon-beta in multiple sclerosis patients. - 260 p.

Source: Dissertation Abstracts International, Volume: 65-12, Section: B, page: 6314.

Thesis (Ph.D.)--State University of New York at Buffalo, 2005.

Multiple sclerosis (MS) is demyelinating, autoimmune disease of the central nervous system and the most common cause of acquired neurological dysfunction during young adulthood. The cause of MS is unknown but it is widely accepted that MS is a complex polygenic disease involving the interplay of multiple genes, gene-gene interactions and post-transcriptional regulatory mechanisms.

ISBN: 0496895486Subjects--Topical Terms:

1017737
Health Sciences, Pharmacy.

Genomic effects of interferon-beta in multiple sclerosis patients.
LDR:03440nmm 2200361 4500 001 1815642
005 20060710080750.5
008 130610s2005 eng d
020 $a 0496895486
035 $a (UnM)AAI3156977
035 $a AAI3156977
040 $a UnM $c UnM
100 1 $a Santos, Roseane Maia. $3 1905057
245 1 0 $a Genomic effects of interferon-beta in multiple sclerosis patients.
300 $a 260 p.
500 $a Source: Dissertation Abstracts International, Volume: 65-12, Section: B, page: 6314.
500 $a Major Professor: Murali Ramanathan.
502 $a Thesis (Ph.D.)--State University of New York at Buffalo, 2005.
520 $a Multiple sclerosis (MS) is demyelinating, autoimmune disease of the central nervous system and the most common cause of acquired neurological dysfunction during young adulthood. The cause of MS is unknown but it is widely accepted that MS is a complex polygenic disease involving the interplay of multiple genes, gene-gene interactions and post-transcriptional regulatory mechanisms.
520 $a Interferon-beta (IFNbeta) is an approved immunomodulatory agent that slows the progression of disability in MS patients and is indicated for the treatment of the relapsing-remitting form of the disease.
520 $a The unpredictable course of MS after diagnosis is an important motivation for identifying biomarkers for monitoring the response to therapy because no single marker has been shown to be a useful metric.
520 $a Our hypothesis was that gene expression patterns would provide a biological tool to predict differences between MS patients in response to IFNbeta therapy. The specific aims were: (1) Identify patterns of gene expression in lymphocytes of MS patients during and after exacerbation phase; (2) Develop and validate a real-time quantitative polymerase chain reaction (real-time QPCR) methodology to quantify IFNbeta-modulated genes; (3) Validate previous results obtained in our laboratory from DNA arrays using the real-time QPCR; (4) Identify panels of genes uniquely expressed in the peripheral blood mononuclear cells of MS patients during administration of IFNbeta-1a; (5) Assess the dynamics of gene expression of INFbeta-modulated genes to elucidate relevant aspects of the MS disease.
520 $a A significant number of genes were identified from DNA arrays: during exacerbation and recovery the biological processes involved were protein catabolism, T-cell proliferation and cell cycle regulation, all of them mostly localized within the nucleus and the comparison between exacerbation and remission showed localization preferably in the cytoplasm.
520 $a The real-time QPCR assays developed in our study identified at least 4 IFNbeta-modulated genes (Mx1, Mx2, STAT1 and TRAIL) that can be used as markers for IFNbeta response.
520 $a The pharmacodynamic measurements of mRNAs of IFNbeta-modulated genes related to the mechanisms of neuroprotection and bone metabolism, brought new insights to better understand IFNbeta effects, providing new tools for monitoring the therapy that could be used in the near future to individualize dosing regimens.
590 $a School code: 0656.
650 4 $a Health Sciences, Pharmacy. $3 1017737
650 4 $a Health Sciences, Pathology. $3 1017854
650 4 $a Health Sciences, Pharmacology. $3 1017717
690 $a 0572
690 $a 0571
690 $a 0419
710 2 0 $a State University of New York at Buffalo. $3 1017814
773 0 $t Dissertation Abstracts International $g 65-12B.
790 1 0 $a Ramanathan, Murali, $e advisor
790 $a 0656
791 $a Ph.D.
792 $a 2005
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3156977